Did CEOs and officers buy or sell their own stock?
Open-market trades by the people who know the company best, with their own money.
Last 7 days: the stocks insiders bought and sold most
Stocks Koreans hold most · disclosed Last 7 days · open-market trades only
Bought most
Sold most
Whalegun
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Ivan HyepCFO | Bicara TherapeuticsBCAX | Open-market sale10b5-1 plan | 05/21 | 05/26 | 9,200 sh | $20.42 | $187,864 | −6.0% |
CEO | Bicara TherapeuticsBCAX | Open-market sale10b5-1 plan | 05/18 | 05/20 | 15,000 sh2 trades | $20.04avg. | $300,561.42 | −4.0% |
Bicara TherapeuticsBCAX | Open-market sale10b5-1 plan | 05/15 | 05/18 | 12,500 sh2 trades | $20.29avg. | $253,625 | −6.1% | |
David RabenChief Medical Officer | Bicara TherapeuticsBCAX | Open-market sale10b5-1 plan | 04/27 | 04/28 | 5,500 sh | $22.88 | $125,840 | −9.0% |
Ivan HyepCFO | Bicara TherapeuticsBCAX | Open-market sale10b5-1 plan | 04/21 | 04/22 | 9,200 sh | $23.00 | $211,600 | −6.0% |
Bicara TherapeuticsBCAX | Open-market sale10b5-1 plan | 04/20 | 04/20 | 15,000 sh | $23.61 | $354,150 | −4.0% | |
Bicara TherapeuticsBCAX | Open-market sale10b5-1 plan | 04/15 | 04/17 | 12,500 sh2 trades | $23.01avg. | $287,625 | −6.0% | |
David RabenChief Medical Officer | Bicara TherapeuticsBCAX | Open-market sale10b5-1 plan | 03/25 | 03/26 | 5,500 sh | $18.95 | $104,225 | −9.0% |
Ivan HyepCFO | Bicara TherapeuticsBCAX | Open-market sale10b5-1 plan | 03/23 | 03/24 | 9,200 sh | $18.52 | $170,384 | −6.0% |
CEO | Bicara TherapeuticsBCAX | Open-market sale10b5-1 plan | 03/18–03/20 | 03/20 | 15,000 sh3 trades | $18.82avg. | $282,361.26 | −4.2% |
Bicara TherapeuticsBCAX | Open-market sale10b5-1 plan | 03/16 | 03/17 | 12,500 sh2 trades | $19.66avg. | $245,750 | −5.9% | |
Bicara TherapeuticsBCAX | Open-market sale10b5-1 plan | 03/09 | 03/11 | 36,766 sh | $19.17 | $704,804.22 | −9.8% | |
CEO | Bicara TherapeuticsBCAX | Open-market sale10b5-1 plan | 03/04–03/06 | 03/06 | 8,234 sh3 trades | $18.74avg. | $154,317.02 | −2.4% |
Bicara TherapeuticsBCAX | Open-market sale10b5-1 plan | 03/03–03/04 | 03/05 | 16,518 sh2 trades | $18.23avg. | $301,046.85 | −10.2% | |
Bicara TherapeuticsBCAX | Open-market sale10b5-1 plan | 03/03–03/04 | 03/05 | 16,500 sh2 trades | $18.52avg. | $305,566 | −23.0% | |
Bicara TherapeuticsBCAX | Open-market sale10b5-1 plan | 03/03 | 03/05 | 17,392 sh2 trades | $18.16avg. | $315,838.72 | −7.8% | |
RA Capital Healthcare FundDirector | Bicara TherapeuticsBCAX | Open-market buy | 02/26 | 03/02 | 300,000 sh | $16.00 | $4,800,000 | +7.0% |
Bicara TherapeuticsBCAX | Open-market sale10b5-1 plan | 02/25 | 02/27 | 3,631 sh2 trades | $18.04avg. | $65,503.24 | −1.7% | |
Ryan CohlheppPresident and COO | Bicara TherapeuticsBCAX | Open-market sale10b5-1 plan | 01/22 | 01/26 | 3,828 sh | $18.10 | $69,286.8 | −1.8% |
Ivan HyepCFO | Bicara TherapeuticsBCAX | Open-market sale10b5-1 plan | 01/22 | 01/26 | 1,882 sh | $18.15 | $34,158.3 | −1.3% |
